Fragment‐Based Screen against HIV Protease
暂无分享,去创建一个
J. E. Elder | A. Olson | D. McRee | R. Rosenfeld | C. Stout | A. Perryman | Alexander L. Perryman | Qing Zhang | Holly H. Soutter | Robin Rosenfeld | Duncan E. McRee | Arthur J. Olson | John E. Elder | C. David Stout | H. Soutter | Qing Zhang
[1] Peter Kuhn,et al. Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. , 2002, Journal of synchrotron radiation.
[2] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[3] Christopher W Murray,et al. Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.
[4] Ana Gonzalez,et al. Web-Ice: Integrated Data Collection and Analysis for Macromolecular Crystallography , 2008 .
[5] Irene T Weber,et al. Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. , 2006, Journal of molecular biology.
[6] Turkan Haliloglu,et al. Cooperative fluctuations of unliganded and substrate‐bound HIV‐1 protease: A structure‐based analysis on a variety of conformations from crystallography and molecular dynamics simulations , 2003, Proteins.
[7] A. Gronenborn,et al. A solution NMR study of the binding kinetics and the internal dynamics of an HIV‐1 protease‐substrate complex , 2003, Protein science : a publication of the Protein Society.
[8] Wendy A. Warr,et al. Fragment-based drug discovery , 2009, J. Comput. Aided Mol. Des..
[9] J. Pflugrath,et al. The finer things in X-ray diffraction data collection. , 1999, Acta crystallographica. Section D, Biological crystallography.
[10] Irene T Weber,et al. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. , 2008, Accounts of chemical research.
[11] Rieko Ishima,et al. Rapid structural fluctuations of the free HIV protease flaps in solution: Relationship to crystal structures and comparison with predictions of dynamics calculations , 2002, Protein science : a publication of the Protein Society.
[12] J. Andrew McCammon,et al. A coarse grained model for the dynamics of flap opening in HIV-1 protease , 2005 .
[13] T. Merigan,et al. "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. , 2005, Structure.
[14] C. Simmerling,et al. Solution structure of HIV-1 protease flaps probed by comparison of molecular dynamics simulation ensembles and EPR experiments. , 2008, Journal of the American Chemical Society.
[15] J. Barreto,et al. Antiretroviral Drugs , 2007, Journal of clinical pharmacology.
[16] György M Keseru,et al. Hit discovery and hit-to-lead approaches. , 2006, Drug discovery today.
[17] P. Colman. New antivirals and drug resistance. , 2009, Annual review of biochemistry.
[18] H. Jhoti,et al. A new school for screening , 2005, Nature Biotechnology.
[19] Timothy McPhillips,et al. New paradigm for macromolecular crystallography experiments at SSRL: automated crystal screening and remote data collection , 2008, Acta crystallographica. Section D, Biological crystallography.
[20] Elizabeth Connick,et al. Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.
[21] Jung-Hsin Lin,et al. Restrained molecular dynamics simulations of HIV‐1 protease: The first step in validating a new target for drug design , 2006, Biopolymers.
[22] R. Alonso,et al. Cytostatic and Cytotoxic Activity of Synthetic Diterpene Derivatives Obtained from (-)-Kaur-9(11), 16-Dien-19-Oic Acid Against Human Cancer Cell Lines , 2005 .
[23] R. Poljak,et al. The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. , 1991, Biochimie.
[24] D. Goodsell,et al. Identifying Protein Binding Sites and Optimal Ligands , 2005 .
[25] S. Senapati,et al. Molecular dynamics simulations of ligand-induced flap closing in HIV-1 protease approach X-ray resolution: establishing the role of bound water in the flap closing mechanism. , 2008, Biochemistry.
[26] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[27] W. Scott,et al. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. , 2000, Structure.
[28] D. Goodsell,et al. Automated prediction of ligand‐binding sites in proteins , 2007, Proteins.
[29] Mark Israel,et al. XtalView, protein structure solution and protein graphics, a short history. , 2008, Journal of structural biology.
[30] A G Leslie,et al. Biological Crystallography Integration of Macromolecular Diffraction Data , 2022 .
[31] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.
[32] D. Fattori,et al. Fragment-based drug design: combining philosophy with technology. , 2007, Current opinion in drug discovery & development.
[33] S. Kent,et al. Dynamics of "flap" structures in three HIV-1 protease/inhibitor complexes probed by total chemical synthesis and pulse-EPR spectroscopy. , 2009, Journal of the American Chemical Society.
[34] A. Leslie,et al. The integration of macromolecular diffraction data. , 2006, Acta crystallographica. Section D, Biological crystallography.
[35] J. Barreto,et al. Antiretroviral drugs , 2007, Reactions Weekly.
[36] Ladislau C. Kovari,et al. Crystal Structures of a Multidrug-Resistant Human Immunodeficiency Virus Type 1 Protease Reveal an Expanded Active-Site Cavity , 2004, Journal of Virology.
[37] Aina E Cohen,et al. An automated system to mount cryo-cooled protein crystals on a synchrotron beam line, using compact sample cassettes and a small-scale robot. , 2002, Journal of applied crystallography.
[38] J. Mccammon,et al. HIV‐1 protease molecular dynamics of a wild‐type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs , 2004, Protein science : a publication of the Protein Society.
[39] Arthur J. Olson,et al. Viral Evolution in Response to the Broad-Based Retroviral Protease Inhibitor TL-3 , 2001, Journal of Virology.
[40] William A. Lee,et al. Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring. , 2006, Journal of molecular biology.
[41] G. Klebe,et al. Targeting the Open‐Flap Conformation of HIV‐1 Protease with Pyrrolidine‐Based Inhibitors , 2008, ChemMedChem.
[42] V. Hornak,et al. Targeting structural flexibility in HIV-1 protease inhibitor binding. , 2007, Drug discovery today.
[43] Robert M Stroud,et al. Anisotropic dynamics of the JE-2147-HIV protease complex: drug resistance and thermodynamic binding mode examined in a 1.09 A structure. , 2002, Biochemistry.
[44] E. Freire,et al. Adaptive inhibitors of the HIV-1 protease. , 2005, Progress in biophysics and molecular biology.
[45] G. Morris,et al. Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3. , 2006, Journal of molecular biology.
[46] C. Rouzioux,et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time , 2006, AIDS.
[47] B. Torbett,et al. Conformational flexibility in the flap domains of ligand-free HIV protease. , 2007, Acta crystallographica. Section D, Biological crystallography.
[48] G. Fanucci,et al. Interflap distances in HIV-1 protease determined by pulsed EPR measurements. , 2007, Journal of the American Chemical Society.
[49] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[50] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[51] C. Craik,et al. Trapping Moving Targets with Small Molecules , 2009, Science.
[52] C. Simmerling,et al. Drug pressure selected mutations in HIV-1 protease alter flap conformations. , 2009, Journal of the American Chemical Society.
[53] Michael K Gilson,et al. Evaluation of the substrate envelope hypothesis for inhibitors of HIV‐1 protease , 2007, Proteins.
[54] M. Wainberg,et al. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection , 2004, AIDS.
[55] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[56] I. Luque,et al. Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis. , 1998, Biochemistry.
[57] M F Sanner,et al. Python: a programming language for software integration and development. , 1999, Journal of molecular graphics & modelling.
[58] Alexander Hillisch,et al. Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. , 2006, Drug discovery today.